Market Research Logo

Merck KGaA - Product Pipeline Review - 2016

Merck KGaA - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Merck KGaA - Product Pipeline Review - 2016’, provides an overview of the Merck KGaA’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Merck KGaA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Merck KGaA
  • The report provides overview of Merck KGaA including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Merck KGaA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Merck KGaA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Merck KGaA’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Merck KGaA
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Merck KGaA’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Merck KGaA Snapshot
Merck KGaA Overview
Key Information
Key Facts
Merck KGaA - Research and Development Overview
Key Therapeutic Areas
Merck KGaA - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Merck KGaA - Pipeline Products Glance
Merck KGaA - Late Stage Pipeline Products
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Merck KGaA - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Merck KGaA - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Merck KGaA - Drug Profiles
cetuximab
Product Description
Mechanism of Action
R&D Progress
avelumab
Product Description
Mechanism of Action
R&D Progress
choriogonadotropin alfa
Product Description
Mechanism of Action
R&D Progress
cladribine
Product Description
Mechanism of Action
R&D Progress
atacicept
Product Description
Mechanism of Action
R&D Progress
M-2736
Product Description
Mechanism of Action
R&D Progress
pimasertib hydrochloride
Product Description
Mechanism of Action
R&D Progress
sprifermin
Product Description
Mechanism of Action
R&D Progress
tecemotide
Product Description
Mechanism of Action
R&D Progress
tepotinib
Product Description
Mechanism of Action
R&D Progress
BGB-283
Product Description
Mechanism of Action
R&D Progress
BGB-290
Product Description
Mechanism of Action
R&D Progress
DI-B4
Product Description
Mechanism of Action
R&D Progress
L-Praziquantel
Product Description
Mechanism of Action
R&D Progress
M-1095
Product Description
Mechanism of Action
R&D Progress
M-2698
Product Description
Mechanism of Action
R&D Progress
M-2951
Product Description
Mechanism of Action
R&D Progress
M-3814
Product Description
Mechanism of Action
R&D Progress
M-7824
Product Description
Mechanism of Action
R&D Progress
M-9241
Product Description
Mechanism of Action
R&D Progress
MSC-2015103B
Product Description
Mechanism of Action
R&D Progress
pimasertib hydrochloride + voxtalisib
Product Description
Mechanism of Action
R&D Progress
rimeporide
Product Description
Mechanism of Action
R&D Progress
ALX-0751
Product Description
Mechanism of Action
R&D Progress
AS-605240
Product Description
Mechanism of Action
R&D Progress
cilengitide
Product Description
Mechanism of Action
R&D Progress
DDD-498
Product Description
Mechanism of Action
R&D Progress
M-7583
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugates for Oncology
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Aurora B Kinase for Cancer
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit CDK8 for Colorectal Carcinoma
Product Description
Mechanism of Action
R&D Progress
Vaccine 1 for Cancer
Product Description
Mechanism of Action
R&D Progress
Vaccine 2 for Cancer
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit SYK for Inflammation
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit WNT Pathway for Oncology
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Autoimmune Disorder and Oncology
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Multiple Sclerosis
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize TNFR for Cancer
Product Description
Mechanism of Action
R&D Progress
Merck KGaA - Pipeline Analysis
Merck KGaA - Pipeline Products by Target
Merck KGaA - Pipeline Products by Route of Administration
Merck KGaA - Pipeline Products by Molecule Type
Merck KGaA - Pipeline Products by Mechanism of Action
Merck KGaA - Recent Pipeline Updates
Merck KGaA - Dormant Projects
Merck KGaA - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
abituzumab
anastrozole
atacicept
cilengitide
cladribine
Drug to Antagonize Oxytocin Receptor for Pre-term Labor
EMD-1204831
emfilermin
EML-4156
M-1095
matuzumab
MSB-0010445
onercept
Osteopontin
pimasertib hydrochloride
plovamer acetate
sarizotan hydrochloride
tecemotide
tucotuzumab celmoleukin
Merck KGaA - Company Statement
Merck KGaA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Merck KGaA, Key Information
Merck KGaA, Key Facts
Merck KGaA - Pipeline by Indication, 2016
Merck KGaA - Pipeline by Stage of Development, 2016
Merck KGaA - Monotherapy Products in Pipeline, 2016
Merck KGaA - Combination Treatment Modalities in Pipeline, 2016
Merck KGaA - Partnered Products in Pipeline, 2016
Merck KGaA - Partnered Products/ Combination Treatment Modalities, 2016
Merck KGaA - Out-Licensed Products in Pipeline, 2016
Merck KGaA - Out-Licensed Products/ Combination Treatment Modalities, 2016
Merck KGaA - Filing rejected/Withdrawn, 2016
Merck KGaA - Phase III, 2016
Merck KGaA - Phase II, 2016
Merck KGaA - Phase I, 2016
Merck KGaA - Preclinical, 2016
Merck KGaA - Discovery, 2016
Merck KGaA - Pipeline by Target, 2016
Merck KGaA - Pipeline by Route of Administration, 2016
Merck KGaA - Pipeline by Molecule Type, 2016
Merck KGaA - Pipeline Products by Mechanism of Action, 2016
Merck KGaA - Recent Pipeline Updates, 2016
Merck KGaA - Dormant Developmental Projects,2016
Merck KGaA - Discontinued Pipeline Products, 2016
Merck KGaA, Subsidiaries
List of Figures
Merck KGaA - Pipeline by Top 10 Indication, 2016
Merck KGaA - Pipeline by Stage of Development, 2016
Merck KGaA - Monotherapy Products in Pipeline, 2016
Merck KGaA - Partnered Products in Pipeline, 2016
Merck KGaA - Out-Licensed Products in Pipeline, 2016
Merck KGaA - Pipeline by Top 10 Target, 2016
Merck KGaA - Pipeline by Route of Administration, 2016
Merck KGaA - Pipeline by Molecule Type, 2016
Merck KGaA - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report